Release Date: 24/08/21 08:16 Summary: FY21 Full Year Results Investor Presentation Price Sensitive: Yes Download Document 2.75MB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%